This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Ezetimibe
Selective NPC1L1 inhibitor that blocks intestinal cholesterol absorption — the only mechanistically distinct lipid-lowering option you can…
Aliases (5)
Overview
What is Ezetimibe?
Ezetimibe (Zetia, Ezetrol) is a cholesterol absorption inhibitor FDA-approved for hypercholesterolemia, used as monotherapy or in combination with statins. It blocks intestinal absorption of dietary and biliary cholesterol.
Key Benefits
Lowers LDL-C by ~15-20% as monotherapy, additive to statins (~25% extra LDL reduction). Reduces cardiovascular events in IMPROVE-IT trial. Useful for statin-intolerant patients or those needing extra LDL lowering.
Mechanism of Action
Inhibits the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter on enterocyte brush border, blocking cholesterol uptake from the intestinal lumen. Reduces hepatic cholesterol delivery, upregulating LDL receptors.
Pharmacokinetics
▸Brand options4 known
StatusRx (US, EU, most jurisdictions); not scheduled
Peptide Interactions
Mechanism-level synergy. Statins induce NPC1L1 upregulation; ezetimibe blocks the resulting compensation. Standard of care for LDL-C targets that statin mono…
Cleanly additive — ezetimibe pushes hepatic LDL-receptor demand, PCSK9i prevents receptor degradation. Combined LDL drops can exceed 70%.
Both non-statin LDL-lowering paths; bempedoic acid hits ATP-citrate lyase upstream of HMG-CoA reductase. Combo (Nexlizet) is the standard non-statin combo.
Theoretical interference (both compete at NPC1L1) — historical concern, but clinical data shows ezetimibe still works; minor reduction in plant sterol absorp…
Cyclosporine raises ezetimibe AUC ~3-12×. If unavoidable, monitor levels and use lowest effective dose. Not a the user concern.
Bind ezetimibe in the gut and reduce absorption ~55-80%. If both are used, take ezetimibe ≥2 hours before or ≥4 hours after the sequestrant.
Modestly raise ezetimibe AUC; clinical concern is gallstone risk via altered bile composition. Use with caution and monitor; gemfibrozil specifically often a…
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 6
Side Effects
- 1None reaching this threshold in any RCT — ezetimibe is unusually well-tolerated.
- 2Diarrhea (~4%)
- 3Upper respiratory tract symptoms (~4%, possibly background incidence)
- 4Joint pain / arthralgia (~3%)
- 5Mild fatigue (~3%)
- 6Sinusitis-like symptoms (~3%)
When to Stop
- Hepatic transaminase elevation — ALT/AST >3× ULN in <1% of users on monotherapy; up to 2-3% when combined with statin. Usually asymptomatic, reversible on discontinuation. Check LFTs at baseline and at 8-12 weeks.
- Myopathy / rhabdomyolysis — extremely rare with ezetimibe alone; risk is essentially driven by the co-administered statin. Stop both and check CK if unexplained muscle pain develops.
- Cholelithiasis / gallstones — modest signal in some long-term studies, particularly when combined with fibrates. Mechanism: altered bile composition.
- Pancreatitis — very rare, mostly in fibrate-combination context.
- Allergic reactions / angioedema — rare.
- Thrombocytopenia — very rare.
- First 8-12 weeks: baseline LFT and follow-up LFT. Any ALT/AST >3× ULN → recheck and consider stopping.
- Any unexplained muscle pain (especially on statin combo): check CK and reassess.
- Long-term: LFT and lipid panel every 6-12 months once stable.
References
Cannon et al. 2015 — IMPROVE-IT trial, NEJM
landmark RCT, ezetimibe + simvastatin vs simvastatin in post-ACS, n=18,144, 6.4% CV event reduction.
View StudyKim et al. 2022 — RACING trial, Lancet
00916-3/fulltext) — moderate-statin + ezetimibe vs high-statin monotherapy, non-inferior with fewer adverse events.
View StudyBaigent et al. 2011 — SHARP trial, Lancet
60739-3/fulltext) — ezetimibe + simvastatin in CKD, 17% reduction in major atherosclerotic events.
View StudyEzetimibe FDA label (Zetia)
PK, dosing, contraindications, drug interactions.
View StudyMiettinen — cholesterol absorption phenotyping via plant sterols
foundational work on sitosterol/campesterol as absorption markers; basis for the lean-reactor / hyperabsorber concept.
View StudySudhop et al. 2002 — ezetimibe inhibits intestinal cholesterol absorption in humans, Circulation
confirmed mechanism in humans, ~54% absorption reduction.
View StudyDavis et al. — NPC1L1 as ezetimibe target
molecular target identification.
View Study2018 AHA/ACC Cholesterol Guidelines
ezetimibe positioning in modern lipid management.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.